Galmed Pharmaceuticals (GLMD) Non-Current Deffered Revenue (2016 - 2018)

Galmed Pharmaceuticals' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $270000.0 for Q1 2018.

• In Q1 2018, Non-Current Deffered Revenue fell 75.12% year-over-year to $270000.0; the TTM figure through Mar 2018 stood at $270000.0 (down 75.12% YoY), while the FY2017 annual figure was $538000.0, down 50.82% from the prior year.
• Non-Current Deffered Revenue for Q1 2018 stood at $270000.0, down from $538000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $1.1 million in Q4 2016, with the low at $270000.0 in Q1 2018.
• The 3-year median for Non-Current Deffered Revenue is $1.0 million (2016), against an average of $846857.1.
• The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue decreased 22.39% in 2017, then sank 75.12% in 2018.
• Galmed Pharmaceuticals' Non-Current Deffered Revenue stood at $1.1 million in 2016, then sank by 50.82% to $538000.0 in 2017, then plunged by 49.81% to $270000.0 in 2018.
• Business Quant data shows GLMD's Non-Current Deffered Revenue at $270000.0 in Q1 2018, $538000.0 in Q4 2017, and $811000.0 in Q3 2017.